Pfizer, Boehringer Ingelheim Tap MacroGenics In Separate Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.
You may also be interested in...
Deal Watch: Bristol, Janssen Keep The Heat High In Cancer Immunotherapy Deal-Making
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.
MacroGenics Strikes Second Oncology Partnership With Servier
The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.
Servier, MacroGenics Forge Option Deal For Cancer Drug
The French pharma acquires the right to license the antibody MGA271, which has received strong interest since BMS’s Yervoy was approved in March.